HD 1369 prohibits licensed health insurers (subject to specific Massachusetts insurance laws) from requiring annual re-authorizations for prescription drugs treating chronic conditions. It directly affects patients with conditions like diabetes, heart disease, Alzheimer's, cancer, stroke, or respiratory disease, as well as their insurers. The bill's key provision bans insurers from demanding yearly approval for these specific medications once a physician, physician's assistant, or nurse practitioner has prescribed them. This changes the current process by eliminating an administrative hurdle for ongoing treatment of chronic illnesses.
By Mr. Tarr, a petition (accompanied by bill, Senate, No. 830) of Bruce E. Tarr for legislation to preserve community pharmacies by conducting audits on contracts for pharmacy services. Financial Services.
This bill (SD 85) establishes rules for pharmacy benefits managers and covered entities regarding reimbursement rates for prescription drugs. It requires that drugs placed on "maximum allowable cost lists" (reimbursement limits) must meet specific FDA rating criteria and have therapeutically equivalent alternatives available. Pharmacies must receive transparent cost information, and reimbursement rates must cover actual pharmacy acquisition costs (using National Average Drug Acquisition Cost as a benchmark). The bill also creates a 7-business-day appeals process for pharmacies to challenge rates, with retroactive payment adjustments if appeals are approved, and prohibits retroactive discounts on claims. These requirements apply to all pharmacy benefits managers and covered entities operating in Massachusetts.
This bill establishes new duties for pharmacy benefit managers (PBMs), the companies that manage prescription drug benefits for health insurance plans. It requires PBMs to act with care, transparency, and fairness toward patients (enrollees), health plans, and pharmacies, prioritizing patient interests when conflicts arise. Key provisions include mandating clear disclosure of fees and conflicts of interest, prohibiting excessive "spread pricing" (where PBMs retain fees beyond actual drug costs), and requiring transparent processes for formulary decisions and appeals. Violations may result in monetary penalties or license suspension by the state commissioner. The bill directly affects PBMs, health insurers, pharmacies, and patients covered by health benefit plans.
This bill establishes a state-funded program to reimburse Massachusetts seniors aged 65+ with household incomes of $50,000 or less annually for all out-of-pocket prescription drug costs, including insurance co-pays. The state would disburse reimbursements up to $2,500 per person yearly from the General Fund. Eligible individuals must apply through a process defined by the health commissioner, and the program requires annual impact reports to legislative committees, expiring after four years unless renewed by the legislature.
This bill requires pharmacy benefit managers (PBMs) in Massachusetts to set and update drug reimbursement rates based on transparent, standardized criteria. It mandates that PBMs provide pharmacies with timely access to their "maximum allowable cost" lists, allow pharmacies to challenge rates below their actual drug purchase costs, and offer a 7-day appeal process for disputes. Pharmacies can refuse to dispense drugs if reimbursement would be lower than their acquisition cost, and PBMs must reimburse pharmacies at least as much as they pay their own affiliated pharmacies. The law applies to all PBMs serving MassHealth and similar programs, with violations treated as unfair trade practices.
This bill requires pharmacy benefit managers (PBMs) to pay community pharmacies fairly for services, prohibiting practices like "pharmacy steering" (steering patients to PBMs' own pharmacies) and ensuring non-affiliated pharmacies receive equal payment to affiliated ones. It mandates that maximum allowable drug costs for community pharmacies must be at least as high as those paid by Massachusetts Medicaid, with PBMs required to publicly disclose cost-setting methods and update these costs every three business days. Pharmacies can appeal if they believe drug costs are unfairly low or if a drug doesn't meet transparency requirements for inclusion on cost lists. The law directly affects community pharmacies, PBMs, and health benefit plans by standardizing payment fairness and increasing transparency in drug pricing.
This bill establishes a licensing system for specialty pharmacies in Massachusetts that dispense complex medications (like those for cancer or autoimmune conditions). It requires these pharmacies to designate a lead pharmacist who must register with the state, maintain detailed records of dispensed drugs, and report changes annually or after updates. Insurance companies must allow any licensed pharmacy to provide specialty drugs under the same payment terms and cannot block access to these medications. The law directly affects specialty pharmacies (including out-of-state providers needing a license), pharmacists in charge, and insurers, ensuring consistent access to specialty medications within Massachusetts.
HD 3872 requires health insurance plans covering prescription drugs to allow pro-rated daily cost-sharing for partial medication fills when a prescriber or pharmacist determines it benefits the patient and the patient agrees, specifically for medication synchronization. It prohibits insurers from denying coverage for partial fills under these conditions and mandates pharmacies to override system denials for synchronization purposes. The bill also mandates full payment for dispensing fees on partial fills, regardless of any pro-rated patient copay. This directly affects patients managing multiple medications and their insurers, aiming to improve adherence and reduce waste by aligning prescription schedules.
This bill requires pharmacy benefit managers (PBMs) to pass at least 80% of estimated rebates from drug manufacturers to insured patients by reducing their out-of-pocket costs at the pharmacy counter. It directly affects patients (who see lower immediate costs) and PBMs (who must adjust pricing and report compliance). Key provisions include annual reporting to the state commissioner, strict confidentiality rules preventing PBMs from disclosing rebate details (treating them as trade secrets), and penalties for noncompliance (up to $5,000 daily). The law aims to make rebate savings more transparent and directly benefit patients through reduced prescription costs.
